The opioid crisis: Naloxone and pharmacists to the rescue

Gomes T Murray R Kolla G , et al; on behalf of the Ontario Drug Policy Research Network, Office of the Chief Coroner for Ontario and Ontario Agency for Health Protection and Promotion (Public Health Ontario). Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Toronto (ON): Ontario Drug Policy Research Network; 2021.

Alberta Substance Use Surveillance System. Available: https://www.alberta.ca/substance-use-surveillance-data.aspx (accessed Jul. 4, 2021).

Alsabbagh MW Chang F Cooke M , et al. National trends in population rates of opioid-related mortality, hospitalization and emergency department visits in Canada between 2000 and 2017: a population-based study. Addiction June 25, 2021.

So R Al Hamarneh Y Barnes M , et al. The status of naloxone in community pharmacies across Canada. Can Pharm J (Ott) 2020;153:352-6.

Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and stimulant-related harms in Canada. Ottawa (ON): Public Health Agency of Canada; June 2021. Available: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants (accessed Jul. 4, 2021).

Gomes T Khuu W Martins D , et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ 2018;362:k3207.

Choremis B Campbell T Tadrous M , et al. The uptake of the pharmacy-dispensed naloxone kit program in Ontario: a population-based study. PLoS One 2019;14:e0223589.

Cid A Daskalakis G Grindrod K , et al. What is known about community pharmacy-based take-home naloxone programs and program interventions? A scoping review. Pharmacy 2021;9:30.

Green TC Case P Fiske H , et al. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc (2003) 2017;57:S19-27.

Antoniou T Pritlove C Shearer D , et al. A qualitative study of a publicly funded pharmacy-dispensed naloxone program. Int J Drug Policy 2021;92:103146.

Tsuyuki RT Arora V Barnes M , et al. Canadian national consensus guidelines for naloxone prescribing by pharmacists. Can Pharm J (Ott) 2020;153:347-51.